The investigation by the Schall Law Firm into Atara Biotherapeutics for potential securities law violations could lead to negative sentiment among investors. If the company is found to have issued misleading statements or failed to disclose important information, it could result in legal consequences and a loss of investor trust, likely leading to a short-term decline in stock price.